MedTrace Logo

Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

NCT06405295 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-02-14

No results posted yet for this study

Summary

Evaluation of the efficacy and safety of different adjuvant intensification regimens in early-stage BRCA1/2 mutant triple-negative breast cancer.

Conditions

  • Breast Carcinoma
  • BRCA Mutation
  • Adjuvant Drug Therapy

Interventions

OTHER

no intervention

Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Peng Yuan

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-06
Primary Completion
2029-03-01
Completion
2029-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06405295 on ClinicalTrials.gov